OKYO Pharma Limited
OKYO Pharma Limited (OKYO.L) Stock Overview
Explore OKYO Pharma Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
23.2M
P/E Ratio
-4.50
EPS (TTM)
$-0.01
ROE
-1.36%
OKYO.L Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of OKYO Pharma Limited (OKYO.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $1.19.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.50 and a market capitalization of 23.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Gary S. Jacob
7
55 Park Lane, London
2018